Navigation Links
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
Date:5/14/2008

elcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements regarding the further development and potential safety, efficacy, regulatory status, commercial potential and other characteristics of Kosan's product candidates; the continuation of current clinical trials; the initiation of additional clinical trials and the timing thereof and the use of Kosan's financial resources. Words such as "will," "expect," "believe," "may," "intend," "plan," "potential" and similar expressions are intended to identify forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Kosan's current expectations. Forward-looking statements involve risks and uncertainties. Kosan's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the uncertain progress and r
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Clinicient Inc , a leader ... results of an industry survey of how efficiently ... practice owners and administrative staff completed the brand-neutral ... technology and services that improve therapist efficiency. ... published a free 12-page guide to help physical ...
(Date:5/26/2015)... DUBLIN , May 26, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/nghdvl/north_american ) has announced the addition of ... Entry Market by Type (Integrated Computerized Physician ... by Component (Hardware, Software, Services) - Forecast ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:5/26/2015)... 26, 2015  EndoChoice today announced the launch of ... common stock, which will represent 25.6% of its outstanding ... Delaware corporation in connection with the offering. ... be between $15 and $17 per share. The underwriters ... to purchase up to an additional 937,500 shares of ...
Breaking Medicine Technology:Survey: Half of Physical Therapists Underbill For Their Services 2North American Computerized Physician Order Entry Market 2015-2019 2EndoChoice Announces Launch of Its Initial Public Offering 2
... Crisis of Prematurity , , , ... June 16 The widespread use of fertility drugs, not just high-tech laboratory ... premature birth in the United States , experts said today at the March of ... , Working with experts ...
... June 16 The Regence Foundation announced today it has ...  The award recognizes leaders in the field of palliative care . ... grant associated with the award to support continued advancements in palliative care. ... Palliative care is ...
Cached Medicine Technology:Fertility Drugs Contribute Heavily to Multiple Births 2Fertility Drugs Contribute Heavily to Multiple Births 3Regence Foundation Honors Palliative Care Leaders 2Regence Foundation Honors Palliative Care Leaders 3
(Date:5/27/2015)... May 27, 2015 National ... partner, award winning web development and interactive ... announce the launch of its newly redesigned, ... , National Healthcare Providers, is a physician ... in the areas of Radiology, Anesthesiology, Emergency ...
(Date:5/27/2015)... CARSON, California (PRWEB) May 27, 2015 ... in quality drinking water filtration products, has announced ... system is one of the first to pass ... Compounds/Incidental Contaminants. The certification is monumental, proving that ... presence of select pharmaceuticals, over-the-counter medications, and chemicals ...
(Date:5/27/2015)... 2015 Net Pistol proudly welcomes two ... clients: , The Mobility Van Store of Lakeland, Florida, ... in the mobility industry. They have a team of ... or pre-owned wheelchair-accessible van, truck or car. Additionally, they ... lift chairs, three and four-wheel scooters, and manual wheelchairs. ...
(Date:5/27/2015)... The Advanced Fertility Center of Chicago announces that their ... better serve the needs of couples in Chicagoland. The ... Northwest side of the city at 4920 North Central Ave., ... the Chicago office at (773) 794–1818. This is the ... The other 2 offices are in Gurnee and Crystal ...
(Date:5/26/2015)... San Francisco, CA (PRWEB) May 27, 2015 ... innovative and beautiful technology for women, today announces ... jewelry that monitors women’s stress, sleep, activity and ... of jewelry with innovative health tracking technolo- gy, ... to stress levels, to provide women with lifestyle ...
Breaking Medicine News(10 mins):Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 2Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 3Health News:Water, Inc.’s BG-12000 Body Glove Water Filter System Receives NSF/ANSI Standard 401 Certification for Pharmaceutical Emerging Contaminant Reduction 2Health News:Water, Inc.’s BG-12000 Body Glove Water Filter System Receives NSF/ANSI Standard 401 Certification for Pharmaceutical Emerging Contaminant Reduction 3Health News:Net Pistol Continues Success Serving Mobility Dealers 2Health News:The Advanced Fertility Center of Chicago Opens a New Fertility Office Location in Chicago 2Health News:Bellabeat debuts the LEAF - smart jewelry that monitors women’s health. 2Health News:Bellabeat debuts the LEAF - smart jewelry that monitors women’s health. 3
... AED industry-leading commitment to research and developmentGrand opening ... the American Academy of Dermatology (AAD)HAYWARD, Calif., March ... SLTM ) today announced the opening of the ... new product development, facilitate research on the innovative ...
... of Cosmetic Dermatology Finds Over-the-Counter (OTC) Albolene(R) Moisturizing Cleanser as ... Mild to Moderate EczemaEDISON, N.J., March 5 Mild to ... to control and heal this skin condition without a prescription ... in the March 2009 issue of the Journal of ...
... of metabolic syndrome in strained unions, study finds , , THURSDAY, ... an unhappy marriage may be greater for women than men, ... in "strained" unions, those marked by arguing and being angry, ... women in the contentious relationships were more likely to develop ...
... InfoLogix ensures a hospital,s communications system enables more efficient ... nightmare is having its communications system go down. But ... InfoLogix, Inc. (Nasdaq: IFLG ), ... out one of America,s largest and most reliable wireless ...
... Finance New Health Care Proposals At Today,s Summit?WHITE HOUSE TO ... released today by the Republican National Committee:(Logo: http://www.newscom.com/cgi-bin/prnh/20080519/RNCLOGO ) ... Summit : ... On Health Care Issues. "On Thursday, Mr. Obama ...
... EU and US Approvals for Intravenous Formulation of Temozolomide ... PresentationKENILWORTH, N.J., March 5 Schering-Plough Corporation (NYSE: ... and the US FDA both approved the intravenous (IV) ... approved oral form of the drug. Temozolomide is ...
Cached Medicine News:Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 2Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 3Health News:Commonly Used Beauty Staple Clinically Proven to Help Treat Eczema 2Health News:Commonly Used Beauty Staple Clinically Proven to Help Treat Eczema 3Health News:Bad Marriages Harder on Women's Health 2Health News:Bad Marriages Harder on Women's Health 3Health News:InfoLogix Implements Wireless Multi-Site Medical Communications Solution for Sisters of Mercy Health System 2Health News:InfoLogix Implements Wireless Multi-Site Medical Communications Solution for Sisters of Mercy Health System 3Health News:InfoLogix Implements Wireless Multi-Site Medical Communications Solution for Sisters of Mercy Health System 4Health News:InfoLogix Implements Wireless Multi-Site Medical Communications Solution for Sisters of Mercy Health System 5Health News:RNC: Tax and Spend Fever 2Health News:RNC: Tax and Spend Fever 3Health News:RNC: Tax and Spend Fever 4Health News:RNC: Tax and Spend Fever 5Health News:RNC: Tax and Spend Fever 6Health News:RNC: Tax and Spend Fever 7Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 3Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 5Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 6Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 7
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Angled Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Titanium. Straight shafts with 6.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.4 inches....
Titanium. Curved shafts with 5.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.3 inches....
Medicine Products: